RE: Project Optimus4 Dec 2024 14:57
Wael Harb, MD, MBA
Vice President, Medical Management, Oncology @ Syneos Health | Board Certified, Executive MBA
1w
To optimize or not to optimize? The FDA’s Project Optimus is reshaping oncology trials by shifting from maximum tolerated doses to precision dosing strategies.
Key Takeaways:
• Precision Dosing: Emphasizing tailored dosing to enhance patient outcomes. 🎯
• Regulatory Shifts: Introducing new expectations for comprehensive dose-response data. 📊
• Biotech Implications: Emerging biotech companies may face challenges due to increased time and costs associated with these requirements. 💡
For those interested in the evolving landscape of oncology trials and regulatory frameworks, I invite you to listen to our in-depth discussion. Your thoughts and feedback are welcome as we navigate these significant changes in our field.
#Oncology #ClinicalTrials #ProjectOptimus #PrecisionMedicine #Biotech